Repost: To further elaborate on the indirect cost cap of

New Post Public Reply Private Reply Replies (1) Message Board
Respert24
605
Repost:

To further elaborate on the indirect cost cap of 15% for new and existing grants, what the vast majority of non-researchers don't understand (I was included in this group until I started to read up a bit) is that indirect costs make up, on average, 40% of the money used to run research and can run up to 75% in some cases. To be fair here, there are probably some grants that require less than 40% as well, but the average is 40% and this will cripple just about everybody who relies on grants.

From Nature, a journal many here have quoted in regards to LL or related published work, this paragraph was written shortly after a judge temporarily froze the order. Which explains the "would have cut" phrasing:

“The policy, announced late on 7 February by the US National Institutes of Health (NIH), would have cut ‘research overhead’ to 15% for new and existing grants. Last year, the NIH, the largest public funder of biomedical research in the world, awarded US$26 billion directly to scientists to help them pay workers’ salaries and buy equipment and reagents for their laboratories, while $9 billion went to these overhead, or indirect, costs, to help institutions run their facilities and cover administrative fees. The historical average indirect-costs rate has been about 40%, and goes up to 75% for some institutions.”

https://www.nature.com/articles/d41586-025-00436-1

At that 40% estimate, you go from 10 billion paid out for indirect costs down to under 4 billion. That's 6 billion dollars just, poof, gone. Immediately, with no plans to help make up a shortfall. Hell, not just no plans to make it up. No desire to make it up.

Covid showed us just how hard it is for businesses to float employees for extended periods of time when they're simply unable to operate. While this freeze isn't covid and isn't supposed to last forever, it can and probably will end some research just because of the weeks/months long inability to receive the funds they need to stay alive. Research institutions aren't money making machines.

And that's not even counting the research that could/will end when they aren't on a freeze any longer but receiving a third of what's necessary to fund their initiatives. How do they continue when it's literally not feasible to pay for the people, lab access, materials, and equipment necessary to simply perform their research. The short answer is they won't.

And those who might say that the trump administration can't withhold funds now that the judge placed a hold on that plan, there is strong evidence he isn't bothering to comply. A quick question in chatgpt shows that as of two days ago the judge has stated that it appears the administration hasn't fully cooperated.

And yeah, I understand that if you are a fan of what the President is doing it’s easy to let the ol’ liberal bias argument fly but it’s not just liberal leaning news. Its independent and non-partisan and…out of places you wouldn’t maybe expect.

Like this article from a website in a deep red state, that is considered to be non-partisan and focused more on business in the state than politics.

https://www.insideindianabusiness.com/article...nt-funding

“Indiana University School of Medicine researchers received more than $243 million in total funding from the National Institutes of Health during federal fiscal year 2023—a more than $54 million increase over the past five years, or 28%, a university press release said. Data for fiscal year 2024 could not immediately be confirmed.

A press release said this makes the IU School of Medicine No. 13 in NIH funding among all public medical schools in the country and No. 29 among all schools nationally—both a record best for the school.

According to data from a report by United for Medical Research, every $1 million in NIH funding awarded to Indiana researchers in 2022 created nearly 13 jobs, the income and other associated expenses from which generated $2.76 million in economic activity in the state. Based on that data, the IU School of Medicine’s 2023 NIH funding is responsible for creating about 3,142 jobs and an estimated $672 million in annual economic activity in Indiana—more than half of the estimated total $1.02 billion in economic activity generated in Indiana from all NIH funding in the state.”

If you take 40% of that 2023 grant money it's basically 100 million dollars. That's assuming they're right at the average, which may not be true. With that many dollars I'd wager they're higher. But at 40% cut down to 15% that represents a shortfall of over 60 million dollars. We all know what has to happen when that money disappears.

And this is what kills me. There is not a single one of us who can predict what happens when billions or trillions of money that has already been in motion for years is not just suddenly frozen without warning, but then taken away completely. The ramifications are going to be far reaching. Just look at the impact that grant money had on hiring employees and contributing to Indiana's economy?

And that's just little ol' Indiana.

The university isn't going to close, but people will lose their jobs. Some of those people are barely getting by, or sliding backwards every year with the cost of living increases or surprise medical bills. They have homes they can lose, kids that need food. It's insane that ANY administration thinks they can, relatively out of the blue, just halt such a massive and intricate machine as if they know better. They don't. The people who are in the machine, who have built the machine, who run it and service it are the ones who know and they resoundingly are trying to tell us this will be crippling.

Why on earth would you not let these in-motion programs continue while you embed yourself and take the time to learn how to make smart choices that don't amount to forcing an engine to blow a rod and thinking it'll be great for the engine. Look at how smooth this engine is going to run now that we reduced the number of rods it needs to use!

Cytodyn is potentially tied to at least two grants for major initiatives we're hoping help get LL to market and our investments to a happy place. That success is also tied to the FDA, which very well might get the same treatment as the NIH. We have a lot of shots on goals and I want all of them to remain available and on track.

But unfortunately, it is a very real possibility that Cytodyn is slowed down considerably by decisions like this. Maybe not directly, but certainly indirectly. Maybe we'll end up ok. Maybe the foundations we have lining up to run pilot studies or help get LL over the line in HIV Cure have money in the bank already and won't be slowed down or have to cut the programs looking to explore LL. Maybe Gates can convince Trump that directing funds to cure HIV should be an outlier and get funding approved where it may otherwise be taken away.

But, like the people making decisions to freeze and ultimately limit NIH funds, it's impossible to make a reasonable argument that we know for sure things won't get fubar'd backwards to when fubar was a more popular term.

This has been my long and winding road to the point I wanted to make.

Please stream Tango and Cash. It's a banger.

#Science

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 3

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 3

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 5

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 6

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading

Top 5 Most Recently Viewed Articles

OPENLANE's Strategic Repurchase Enhances Shareholder Value

Updated Category News Views 163

OPENLANE Strengthens Position with Series A Stock Repurchase OPENLANE, Inc. (NYSE: KAR) has announced a significant development in its corporate strategy by successfully repurchasing 53% of its Series A Convertible Preferred Stock. This strategic move underscores OPENLANE's robust market presence as a dominant operator in digital marketplaces for wholesale used vehicles....

Continue Reading
Wingstop Faces Challenges Amid Shifting Consumer Preferences

Updated Category News Views 340

Wingstop's Recent Financial Performance Overview Wingstop Inc. (NASDAQ: WING) shares saw a noticeable surge following the release of their latest financial results. Although the company reported earnings of $1.09 per share, which is an improvement from $0.89 the previous year, overall revenue did not meet Wall Street expectations. The reported total revenue of $175.74...

Continue Reading
XPO Recognized as a Top Reliable Company for 2025 by Newsweek

Updated Category News Views 47

XPO Shines as One of America’s Most Reliable Companies XPO (NYSE: XPO), recognized as a premier provider of freight transportation in North America, has recently been named one of the prestigious 'Most Reliable Companies' for 2025 by Newsweek magazine. This accolade is part of Newsweek's inaugural list that celebrates U.S.-based companies noted for their unwavering...

Continue Reading
Man Group PLC Details Declarations for Market Investors

Updated Category News Views 113

Important Information Regarding Man Group PLC's Position Man Group PLC has recently provided an overview of its investment interests and positions in American Axle & Manufacturing Holdings Inc. This disclosure is crucial for shareholders and potential investors looking to understand the company's current market stance. Key Disclosures from Man Group PLC Under Rule 8.3 of...

Continue Reading
Flex Ltd. Schedules Quarterly Results Financial Call

Updated Category News Views 190

Flex Ltd. Sets Date for Upcoming Earnings Call Flex (NASDAQ: FLEX) has recently announced an important date for shareholders and stakeholders to mark on their calendars. The company will unveil its financial results for the fourth quarter and fiscal 2025 before the market opens on a Wednesday in May. This event is eagerly anticipated as it provides insights into Flex’s...

Continue Reading